Daily Judi: Wednesday, December 28, 2022
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
A National Institutes of Health phase 2 clinical trial of the immunotherapy drug, atezolizumab, has concluded, and results are being prepared for publication. Atezolizumab, developed by Genentech, is the first treatment targeting the rare cancer, advanced alveolar soft part sarcoma (ASPS), which mostly affects young adults and adolescents. (NIH)
University of Missouri's Amanda Hinnant and Ciera Kirkpatrick, speak to Cameron Conner about two demographic studies on participation in clinical trials. (Missourinet)
Hendrik Isebaert, CEO of Showpad, details how digital transformation may shape medical device sales in the near future. (pharmaphorum)
Ultimate Guitar recounts how wildly successful record sales for the Beatles in the 1960s, led one researcher, Godfrey Hounsfield, to invent life-saving CT-Scans, for which he was awarded the Nobel Prize in 1979.
Our Culture
“We create a template so we can pull back the timelines and eliminate concerns around quality and risk—because everything’s already validated in the design. Then we can work faster with no risk to quality.”
–Jamie, Trial Delivery
About Judi
Judi speeds and improves the world's clinical trial workflows. Our cloud-based platform has 120,000 users across 168 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.
